Abstract: A crucial event in the inflammatory response is recruitment of polymorphonuclear leukocytes (PMNL) to a site of infection or injury. PMNL-epithelial interactions involve many fundamental cell processes, including adhesion, migration, secretion, phagocytosis and apoptosis. Thus, migration of PMNL across epithelial-lined organs is a primary event component of host defense. Moreover, PMNL transepithelial migration often results in disease symptoms. New insights into leukocyte-epithelial signalling mechanisms have emerged that are beginning to shed light on the role of many molecular interactions in regulating the rate of PMNL transepithelial migration. Knowledge of the basic mechanisms that control the activation of pro-inflammatory transcription factors, and how these innate immune signalling pathways lead to an activation of the adaptative immune response that maintains the chronically inflamed state, is essential for pharmacological manipulation of intestinal inflammation. This review highlights recent advances in our understanding of the different mechanisms of PMNL-epithelial cell adhesive interactions at the level of cell surface protein-protein binding events, and in intracellular signal transduction pathways that regulate the PMNL transepithelial migration. Finally, the potential modulation of these different signal pathways as possible therapeutic goals will be discussed.
INTRODUCTION
Polymorphonuclear leukocytes (PMNL) are an important component of innate immunity and their influx into mucosa characterizes many inflammatory diseases [1] . More precisely, migration of PMNL across epithelial linings is a hallmark of several gastrointestinal (GI) disorders (Fig. 1A) . Thus, an acute GI inflammation is observed in bacterial infection caused by different pathogens such as Helicobacter pylori, pathogenic Escherichia coli (EC), Salmonella, Shigella and Yersinia strains. Moreover, the presence of PMNL is noted in gastroenterocolitis induced by ischemic conditions, and by various toxic or drugs. PMNL transepithelial migration is also a key feature of acute phase of idiopathic inflammatory bowel diseases (IBD) (Crohn's disease and ulcerative colitis). Moreover, the degree of PMNL infiltration in intestinal mucosa is one of the most important criteria of disease activity [2] . All these GI tract inflammatory diseases involve several hundred million individuals in the world and are responsible for high morbidity and mortality rates. Moreover, chronic acute inflammation disorders of the GI tract are preneoplastic conditions. Thus, patients with IBD have an increased risk of developing large bowel adenocarcinoma (Fig. 1B) . Whereas, the initial mechanisms underlying the different steps between infection, chronic inflammation and cancer are poorly understood, PMNL certainly play a major role in the pathogenesis of epithelium injury. Thus, the persistence of a severe local acute inflammatory response may result in dysplasia and neoplasia in intestinal epithelia. Understanding of the different mechanisms that trigger PMNL influx into mucosa and leukocyte interactions with digestive epithelial cells is a major challenge for the development of new therapeutic strategies against the inflammatory disorders and/or the bacterial infections. Recent advances in our understanding of the mechanisms of PMNLepithelial cell adhesive interactions may be crucial for a comprehensive approach to digestive carcinogenesis.
This review summarizes our current knowledge concerning the molecular events that occur following interactions between PMNL and intestinal epithelial cells. We will first describe different tools for studying such interactions. Then, the different molecular mechanisms knwn to underlie these interactions, and the different consequences induced on the epithelial barrier integrity are presented. Finally, the potential targets for therapeutic intervention during the inflammatory process occuring in digestive diseases, particularly in IBD, are discussed.
HOW TO INVESTIGATE THE PMNL-INTESTINAL EPITHELIAL CELL INTERACTIONS

In Vitro Model
Different polarized cell lines (e.g., HT-29, Caco-2, T84, etc) can be used to observe interactions between pathogens, toxins or different drugs and intestinal epithelial cells [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Conversely, only a few in vitro models have been used to study PMNL-intestinal epithelial cell interaction. PMNL migration across epithelial surfaces can be modeled using cultured epithelial monolayers grown on filters [14, 15] (Fig.  1C) . On the basis of the initial work of James L Madara and colleagues [15] [16] [17] [18] [19] [20] [21] , we and others have appreciated the power of the T84 model which consists of growing T84 cells on filters in polarized monolayers [6, 12, 22, 23] . Such highly differentiated epithelial cells cultured in vitro form monolayers that closely resemble the epithelial surface of the gastrointestinal tract [15, 19] . T84 cells have phenotypic and functional properties analogous to cells in the intestinal crypt [15, 19] , the site at which PMNL transmigration predominantely occurs during active intestinal inflammation. By using the T84 model, it has been demonstrated that the pathway of PMNL migration is paracellular (i.e. across interepithelial tight junctions), and that as a result of transjunctional migration, epithelial barrier function can be impaired [15] . Finally, T84 is a human cell line, thus permitting the use of human derived PMNL to study the biology of PMNL/colonocyte interactions [10, 11, 14, 22, 23] (Fig. 1C) .
Animal Models
Animal models, particularly in digestive diseases, have proven to be extremely valuable tools for testing the efficacy of therapeutic agents and for investigating the mechanisms of pathogenesis [24] . Despite the varying nature of these models, results from animals studies provide compelling evidence that environmental factors affecting genetically susceptible hosts are responsible for the induction of IBD. However, an appropriate or an optimal animal model should display certain key characteristics: the gut should exhibit morphological alterations, inflammation, symptoms and signs, pathology, and a course of disease similar or identical to the human IBD. Finally, the animal of interest should have a well-defined genetic background in addition to a welldefined criteria for successful management and manipulation. Animal models of IBD can be categorized into five broad classes: gene knockout models, transgenic mouse and rat models, spontaneous colitis models, adoptive transfer models, and inducible colitis models [24] . These latter models seem well suited to adress the initial steps of acute inflammation occuring in large bowel diseases. Different inducible colitis models have been described, including aceticacid-induced colitis [25] , iodoacetamide-induced colitis [26] , indomethacin-induced enterocolitis [25] , trinitrobenzene sulfonic acid (TNBS)-induced colitis [27] , oxazolone colitis peptidoglycan-polysaccharide colitis [28] and dextran sodium sulfate (DSS) colitis [29, 30] .
Human Tissues
Several methods can be used to study the PMNLepithelial cell interactions in human digestive tissue specimens, such as histological and immunohistochemical studies (both from frozen and paraffin-embedded tissue samples), immunoblotting, Western blotting, Northern blotting, tissue microarrays, DNA arrays and different technics of polymerase chain reaction analysis [31] [32] [33] .
REGULATION OF PMNL ACTIVATION AND MI-GRATION ACROSS INTESTINAL EPITHELIUM BARRIER
Many studies are currently focusing on the events signaling the initiation of PMNL transepithelial migration with a particular interest in the role of bacteria in inducing mucosal inflammation [34] [35] [36] [37] [38] [39] [40] [41] [42] . The interaction of bacteria with intestinal epithelial cells is one of the most frequent stimuli inducing afflux of PMNL [36] . In one of the first studies using the T84 model, the team of James L Madara showed that the application of S. typhimurium organisms to the surface of T84 epithelial cell monolayers led to the production of interleukin 8 (IL-8) and an initially unidentified transcellular chemotactic factor (TCF) that caused translocation of PMNL across the monolayer [37] [38] [39] . This PMNL transepithelial migration across the T84 monolayers was also obtained with another enteroinvasive organism, Shigella sp. [41] . McCormick and coworkers then demonstrated that Salmonella does not require epithelial invasion to stimulate PMNL transmigration [37] . Moreover, a secreted extracellular Salmonella product, SipA, is sufficient to stimulate a protein kinase C (PKC)-dependent signaling cascade that ultimately leads to PMNL transmigration [37] . Because IL-8 expression, like that of most inflammatory responses genes, is in large part regulated by the transcription factor NF-kB, the ability of certain strains of Escherichia coli, the enteropathogenic EC, to activate this factor has been investigated and indeed demonstrated [42] . We have recently shown that PMNL transepithelial transmigration can be induced by the Afa/Dr diffusely adhering E coli infection of polarized T84 monolayers [34, 35] . In this case, PMNL migration was correlated with a basolateral secretion of IL-8 by intestinal T84 cells, but was abolished after incubating epithelial cells with an anti-decay accerating factor (DAF/CD55) antibody that recognizes the short consensus repeat 3 (SCR3) domain of DAF [35] . PMNL transepithelial migration induced by Afa/Dr DAEC was dependent on activation of mitogen-activated protein (MAP) kinases [34] . Interestingly, we observed that the PMNL transepithelial migration induced the epithelial synthesis of tumor necrosis factor and IL-1 , which in turn upregulated expression of Afa/Dr adhesins receptor, DAF, at the apical pole of the monolayer, thereby increasing the adhesion of Afa/Dr DAEC bacteria [35] . Interestingly, a recent study has demonstrated that DAF may play an anti-adhesive role in PMNL transepithelial migration [43] . Other pathogens can trigger PMNL transepithelial migration enabling the microorganism to access their host receptors located to the basolateral side of the epithelium. In other words, by transiently perturbing monolayer integrity, PMNL transepithelial migration can be associated with a window of risk in which luminal pathogens can access basolateral ligands. Thus, PMNL transmigration induced by Yersinia pseudotuberculosis through the opening of tight junctions, allows these bacteria to adhere to their basolateral receptor, the 1 integrin [40] . Finally, we and other have shown that the infection of T84 epithelial cells by certain strains of H. pylori can induce IL-8 secretion and then trigger PMNL transepithelial migration [12] . Thus, after bacteria adhesion usually to the apical surface of epithelium, intestinal cells secrete IL-8 at the basolateral side. However, some receptors, namely Toll-like receptors, particularly TLR5, the receptor for the Gram negative bacterial product flagellin, is restricted to the basolateral side of the intestinal epithelium [44] . Thus, activation of TLR5 by flagellin has been linked to activation of a proinflammatory cascade resulting in basolaterally polarized secretion of IL-8 [44] . Thus, altered mucosal permeability described in chronic IBD, could result in activation of basolaterally expressed TLR5 by flagellin delivered through a paracellular space.
The different chemoattractants for PMNL include bacterial products such as N-formylated peptides, host-derived products (chemokines such as IL-8, phospholipides such as leukotrienes B4, platelet-activating factor, and lipoxins), and products of immune activation such as complement fragments (C3 or C5a). These chemoattractants not only elicit directed motility, but also induce PMNL degranulation, Ca++ mobilization, and release of reactive oxygen intermediates. Other agents can induce PMNL chemotaxis, with minimal activation of other cellular functions: macrophage-inflammatory proteins 1 and 2, cytokine-inductible PMNL chemoattractant, substance P [45] . PMNL transepithelial migration is dependent on the ability of migrating cells to sense gradients of such chemokines and chemoattractants. Moreover, modulation of PMNL transepithelial migration can occur when epithelial cells are exposed to certain cytokines such as INF- [46] . The different molecules described above can induce migration of PMNL to the epithelia, but not allow the PMNL to reach the digestive lumen. In inflammatory events, it has been demonstrated that another molecule, the eicosanoid hepoxilin A (3) [hepA(3)], is synthesized by epithelial cells and secreted from their apical surface [47, 48] (Fig. 2) . HepA (3) acts to attract PMNL via the establishment of a gradient across the epithelial tight junction complex [48] .
MOLECULAR EVENTS OCCURING DURING CELL SURFACE INTERACTION BETWEEN INTESTINAL EPITHELIAL CELLS AND PMNL
Many complex cell surface protein-protein interactions serve to regulate PMNL transepithelial migration (Fig. 2) .
Several data clearly demonstrate that the 2 integrin CD11b/CD18 is central in regulating early adhesive events in the transepithelial migration response [49] . Thus, PMNL migration across the intestinal barrier can be blocked with antibodies to the PMNL 2 integrin CD11b/CD18 [49] . Moreover, leukocytes deficient in 2 integrins fail to transmigrate. Some studies have suggested that, the I domain of M subunit and a lectin-like domain on CD11b play a role in ligand binding and cell adhesion [50, 51] . However, the ligands of these domains are currently unknown. CD11b mediated adhesion is upregulated under inflammatory conditions [52] . ICAM-1, the best-characterized cellular ligand for CD11b/CD18 is an attractive candidate epithelial receptor. However, ICAM-1 is not expressed on intestinal epithelia except during inflammatory conditions or invasion by certain bacterial pathogens, and it is upregulated on the apical rather than basolateral surface [53] .
Another cell surface protein that has been shown to play an important role in modulating PMNL transmigation across epithelia is CD47. Several studies have shown that anti-CD47 antibodies strongly inhibit PMNL transmigration across intestinal epithelium [54, 55] . Moreover, CD47 expressed on both PMNL and epithelial cells regulates PMNL transepithelial migration [54, 55] . In fact, experimental evidence suggests that CD47 regulates the rate of PMNL transepithelial migration, however it but does so after initial adhesion events have occurred [54] [55] [56] . Different reports of CD47 binding to an IgSF member, signal regulatory protein (SIRP) , strongly suggest that CD47-SIRP interactions are important in regulating PMNL transmigration [57, 58] . Inhibitory effects of anti-SIRP antibodies and soluble CD47 fusion proteins have been demonstrated in PMNL transepithelial migration assays [57, 58] . However, the details of how CD47 interacts with SIRP in PMNL to regulate migration remain to be determined [58] .
Members of a family of transmembrane immunoglobulin superfamily proteins termed junctional adhesion molecules or JAMs, have been shown to play roles as adhesion receptors during PMNL transmigration [59, 60] . Multiple members of the JAM protein family have been shown to localize to intercellular junctions [61] [62] [63] . It has been demonstrated that among these different molecules, JAM-C regulates transepithelial migration of PMNL at the level of epithelial desmosomes [60] . Thus, both antibodies against JAM-C and JAM-C fusion proteins inhibit PMNL transepithelial migration. PMNL interactions with epithelial JAM-C occur at points distal to initial adhesive interactions with the epithelial basolateral membrane, thus lending further support for the existence of multiple epithelial ligands for migrating PMNL.
One important physiological consequence of apical PMNL activation is epithelial chloride secretion (Fig. 3) , resulting in fluid movement into the lumen and flushing of the pathogens out of the bowel. Previous reports have demonstrated that 5'-AMP released by PMNL into the lumen is converted to adenosine by CD73, followed by stimulation of lumenal chloride secretion through interaction with apically expressed adenosine A2b receptors [64] [65] [66] [67] . In parallel, IL-6 was found to be apically released by epithelial cells during PMNL transepithelial migration [65] . After migration, PMNL are retained at the apical epithelial surface in many inflammatory conditions. Thus, deposition of immunoglobulin on the apical epithelial suface might serve to promote retention and activation of transmigrated PMNL [68] . IgG1 antibody against an epithelial antigen that retains PMNL at the apical surface has been described. This IgG1 retains PMNL via Fc-mediated adhesion and is antigen-specific [68] . Finally, ICAM-1, markedly upregulated on the apical surface under inflammatory conditions, might serve as a foothold for PMNL on the lumenal surface.
CONSEQUENCES OF PMNL MIGRATION ACROSS THE INTESTINAL EPITHELIAL BARRIER
IBD consisting of UC and CD typically display a waxing and waning course punctuated by disease flares that are characterized by transepithelial migration of PMNL and altered barrier function. The mechanisms by which PMNL elicit the opening of tight junctions during IBD is, to date, not completely established. PMNL certainly disrupt the tight junctions by means of a mechanical action, yet the putative role of proteases and cytokines which may be produced by PMNL after their activation has been determinated [69] [70] [71] . Several studies have focused the analysis of tight junction and adherens junction protein expression in intestinal mucosal tissue obtained from patients with IBD [33, 72] . These studies revealed a global down-regulation of occludin in IBD colonic epithelium encompassing both areas with active inflammation and regions distant from intraepithelial PMNL. Moreover, several tight junction and adherens junction proteins, such as claudin-1, Jam, ZO-1, E-cadherin andcatenin [73] , showed a downregulation exclusively in epithelial cells adjoining transmigrating PMNL [33, 72] . This would suggest that loss of these intercellular junction proteins is a transient process that is rapidly reversible after PMNL transmigration. It has been postulated that downregulation of tight junction proteins during PMNL transepithelial migration might be induced by the migrating leukocytes themselves either by stimulating epithelial cells to reorganize their tight junction and adherens junction components or simply by mechanical forces [74] .
After migrating through the tight junction, PMNL reach the digestive lumen, where there are several functional consequences. First, PMNL can act to destroy lumenal pathogens via activation of the NADPH oxidase. Whereas, NADPH oxidase activation and superoxide release by PMNL during migration aids in pathogen clearance. It also promotes intestinal epithelial cell toxicity. In this regard, several investigators have shown that the inhibition of nitric oxide causes many of the hallmark features of intestinal inflammation, whereas the delivery of exogenous nitric oxide reduces the sequelae of acute inflammation. NO can reduce superoxide-induced damage either by inhibiting NADPH oxidase and superoxide release from PMNL, or by scavenging PMNL-derived superoxide [75, 76] . Interestingly, a recent study demonstrated that nitrite can enhance PMNLinduced DNA strand breakage in epithelial cells by inhibition of myeloperoxydase [77] . Some of our previous work has focused on the initial consequences of acute inflammation in intestinal epithelial cells [22] and PMNL [23] behaviour. IBD are characterized by both transepithelial migration of PMNL and extensive cell death in the affected areas of the intestine. We tie these two phenomena together with our finding that PMNL transmigration can induce epithelial apoptosis [22] . Little apoptosis occurs if the PMNL are in contact with, but not migrating through, epithelial monolayers growing in vitro [22] . Even when extensive death does occur, the death-inducing Fas ligand (FasL) and its receptor are not involved, although they are both present. However, we showed that epithelial cell death can be successfully triggered, however, by actin depolymerization which leads to caspase activation and death with the same time course as that seen after transmigration [22] . In parallel experiments, we showed that transepithelial migration induced by IL-8 or fMLP delays apoptosis of PMNL [23] . Thus, among the different stimuli modulating PMNL apoptosis [78] , transepithelial migration seems to be an important event. Increased survival of transmigrated PMNL was associated with a decrease of surface FasL, and of procaspase-3, -6, -7 and -8 expression, while activation of Erk and p38 MAPK do not appear to be involved in transmigration-mediated PMNL apoptotic protection [23] .
NEW PERSPECTIVES CONCERNING THE THERA-PEUTIC STRATEGIES AGAINST THE INFLAMMA-TORY BOWEL DISEASES
Conventional therapy for IBD rely on corticosteroids and 5-aminosalicylates combined with immunosuppressive agents for maintenance. Corticosteroids and 5-Aminosalicylates target the inflammatory process at different levels. 5-Aminosalicylates influence the production of prostaglandins and leukotrienes, PMNL chemotaxis and the scavenging of reactive oxidative radicals. The effects of corticosteroids are also pleiotropic and partially understood. Drugs such as azathioprine and methotrexate are used for patients dependent on steroids or with steroid refractory disease. However, these drugs may inflict serious side effects. For this reason, fundamental research on the inflammatory pathways underlying IBD has boosted therapeutic interventions with compounds that act at different sites. Actually, a variety of biological agents (such as different monoclonal antibodies, antisense molecules and recombinant proteins) are being developped or used in IBD treatment. These drugs mainly inhibit effector functions of activated macrophages, monocytes, dendritic cells, and PMNL. The most prominent candidates for new biological treatments are the anti-TNF drugs. Monoclonal antibodies against the pro-inflammatory cytokine TNF , such as infliximab or CPD571, have been successfully applied as a treatment for CD [79] . However, the mechanism of action of infliximab remains illusive. Thus, the neutralization of TNF in the inflamed mucosa is unlikely to be a sufficient explanation since many other pro-inflammatory cytokines or molecules can do the job instead [80] . Antibody dependent cytotoxicity, lysis of TNF producing cells by complement fixation or apoptosis induction of T-cells by the Fc portion of the antibody seem to be a more appropriate explanation [81] [82] .
Integrin targeted monoclonal antibodies have been also developed. Thus, a humanized monoclonal antibody of the IgG4 class which recognizes 4 integrin (that dimerizes with 1 subunit or 7 subunit), natalizumab, has been used in IBD patients [83, 84] . Natalizumab may block the migration of leukocytes to the inflamed mucosa in IBD. Use of monoclonal antibodies targeting different cytokine signaling pathways, such as IL-2 receptor, IL-12, IFN-, IL-18 may be trialed in IBD patients [83] . Moreover, another cytokine, IL-10, has been suggested as a potential therapy for IBD [83, 85] . IL-10 inhibits mainly effector functions of activated macrophages, monocytes, dendritic cells and PMNL [86] .
Antisense molecules, such as molecules targeting ICAM-1 have been used without success in patients with IBD [87, 88] . Previous work has largely demonstrated that NF-kB is a key regulator of the epithelial cell innate immune response induced by different bacteria [89] . In this regard, a molecule targeting the p65 subunit of NF-kB holds great promise, but no studies in humans have been reported at present. This molecule could be of interest since in both IBD, particularly in CD, increased activation of NF-kB may be involved in the regulation of the inflammatory response. Moreover, It has been previously demonstrated that nuclear levels of NFkB p65 were increased in lamina propria biopsy specimens from patients with CD in comparison with patients with UC and controls [90] . Parallel to the development of the biological drugs described above, conventional drugs have been subject to renewed interest because of their specific action on the synthetic pathways of proinflammatory cytokines. Novel small molecules sharing these properties are now trialed. Thus, analogous to NF-kB, the mitogen activated protein kinases (MAP-kinase) constitute major pro-inflammatory cascades from the cell surface to the nucleus. The p38 MAPkinase cascade is associated with cell growth, cell differentiation, cell death and inflammation [91] . A targeted inhibition of the p38 MAP-kinase pathway resulted in reduced levels of lipopolysaccharide induced TNF production in several animal models [92] . Moreover, p38 MAPK is activated in the mucosa of patients with active CD and significantly increased when compared to levels in mucosal biopsies of healthy controls [93] . Thus, MAP-kinases are promising targets for immune modulation [91, 93] .
In conclusion, new therapeutic approaches to the treament of IBD should be based on our knowledge of the immunological mechanisms that characterize the pathogenesis of the diseases. The great success of the anti-TNF antibodies has boosted research towards other inflammatory compounds. However, new therapeutic strategies should avoid different drawbacks such as formation of antibodies (resulting in diminishing therapeutic efficacy and infusion reactions), very high cost in producing the drugs and the necessity of intravenous dosing.
